Article
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
Clinical cancer research : an official journal of the American Association for Cancer Research - 3 Sept 2024
Geurts Birgit S, Zeverijn Laurien J, Leek Lindsay V M, van Berge Henegouwen Jade M, Hoes Louisa R, van der Wijngaart Hanneke, van der Noort Vincent, van de Haar Joris, van Ommen-Nijhof Annemiek, Kok Marleen, Roepman Paul, Jansen Anne M L, de Leng Wendy W J, de Jonge Maja J A, Hoeben Ann, van Herpen Carla M L, Westgeest Hans M, Wessels Lodewyk F A, Verheul Henk M W, Gelderblom Hans, Voest Emile E
Abstract excerpt
PURPOSE: To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing-based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients included in the Drug Rediscovery Protocol (NCT02925234). PATIENTS AND METHODS: Patients with solid, treatment-refractory, microsatellite-stable tumors were enrolled in cohort A: breast...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.